Gilead Announces Phase 3 Results from the First Study to Evaluate Switching from TDF-Based Regimens to a TAF-Based Regimen Containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide (E/C/F/TAF)
VANCOUVER, July 21, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48 week data from an open-label Phase 3 study (Study 109)…